Overview of Dianorm (Gliclazide)

Property	Description
Active Ingredient	Gliclazide
Form	Tablet (Often modified-release)
Pharmacological Class	Oral Hypoglycemic Agent / Sulfonylurea Derivative
General Purpose	Blood Glucose Control
Origin	Synthetic Compound

Gliclazide's Identity and Pharmacological Classification

Dianorm is a trade name for a prescription-only medicine containing the synthetic compound Gliclazide as its active substance. Gliclazide is classified as an Oral hypoglycemic agent, whose general purpose is to assist in achieving blood glucose control. This medicine belongs to the Second-generation sulfonylurea class of antidiabetic drugs. Its chemical identity as a sulfonylurea derivative confirms its role in the treatment landscape for Type 2 diabetes mellitus.

The mechanism of Gliclazide involves its action as a primary insulin secretagogue (C15H21N3O3S), highlighting its ability to stimulate insulin release directly. Gliclazide is recognized for its high degree of pancreatic beta-cell selectivity, a characteristic feature distinguishing it from some older sulfonylurea agents. Gliclazide is used for the management of non-insulin-dependent diabetes.

Composition, Form, and General Therapeutic Role

The active ingredient, Gliclazide, is administered via the oral route as a solid dosage form, typically in the form of a tablet. This product is a single-ingredient product, comprising the Gliclazide compound along with necessary excipients, which are often used to create a modified-release tablet. The modified-release form is a pharmaceutical preparation designed to release the active ingredient slowly over an extended duration, a feature often used to support patient adherence.

The primary physiological action involves the stimulation of insulin release from the pancreatic beta-cells, providing a mechanism for promoting a glucose-lowering effect. This action facilitates the management of Type 2 diabetes mellitus in adults, establishing Gliclazide's general therapeutic role in maintaining consistent blood sugar levels throughout the day.

Regulatory References

Gliclazide Retard Mylan 30 mg, modified release tablets - Public Assessment Report Scientific discussion

What side effects are possible with Dianorm (Gliclazide)?

Possible Side Effects and Safety Information

The safety profile of Gliclazide, the active ingredient in Dianorm, is officially documented by government health authorities and is primarily characterized by its glucose-lowering action. Adverse reactions are formally classified by frequency and system-organ class.

Frequency-Classified Adverse Reactions

The most important and common adverse reaction listed in regulatory documents is hypoglycaemia, reflecting the medicine's role as a blood sugar reducer. This effect is noted to be more likely to occur at the beginning of treatment or during dose escalation. Other common effects involve Gastrointestinal Disorders, such as nausea, vomiting, or diarrhoea, which may be transient.

Rare adverse reactions documented by regulatory sources involve the Blood and Lymphatic System, including serious conditions like agranulocytosis and thrombocytopenia. Rare effects also include disorders of the Hepatobiliary System, such as hepatitis or cholestatic jaundice, with isolated documented progression to liver failure.

Serious Adverse Reactions and Safety Restrictions

Severe hypoglycaemia is classified as a serious adverse reaction that may require clinical intervention. The official safety documentation also lists severe skin reactions, such as Stevens-Johnson syndrome, among the serious but rare risks.

Population-specific safety considerations state that older adults may be more susceptible to hypoglycaemia. Furthermore, the medicine is formally contraindicated in several conditions, including severe renal or hepatic insufficiency, Type 1 diabetes, and during pregnancy and lactation, due to the documented heightened risk to these populations. Individuals with G6PD deficiency carry a documented risk of haemolytic anaemia with sulfonylurea agents.

Overdose and Emergency Response

Dianorm (Gliclazide) Overdose and When to Seek Help

The official regulatory documents state that an overdose of Gliclazide primarily results in severe and prolonged hypoglycemia, which is a life-threatening medical emergency. The severity of the low blood sugar can lead to serious neurological outcomes.

Documented Manifestations and Severe Outcomes

The initial signs of overdose often involve adrenergic symptoms such as sweating, palpitations, and intense hunger. As the condition progresses, neuroglycopenic manifestations may occur, including confusion, reduced awareness, delirium, visual disturbances, and seizures. The most critical outcomes listed in regulatory information are loss of consciousness, coma, permanent brain damage, or death.

Mandated Emergency Response

It is officially required to seek immediate medical attention following any suspected overdose. If the affected person is conscious, they should immediately consume simple carbohydrates (e.g., sugar). If the person is unconscious, emergency services must be called immediately.

Required Monitoring and Special Considerations

Regulatory guidance mandates hospitalization for severe cases. Due to the prolonged presence of the medicine, continuous observation and blood glucose monitoring for 24 hours or more may be required to detect recurrent hypoglycemia. Patients who are elderly or have impaired hepatic or renal function are noted to be particularly susceptible to these severe and protracted effects.

Therapeutic Uses of Dianorm (Gliclazide)

Quick Facts

Primary Use: Helps manage blood sugar levels in adults with Type 2 diabetes mellitus.
Therapeutic Role: May be used when exercise and dietary measures alone are not sufficient.
Benefit: Contributes to an appropriate reduction in blood glucose and HbA1c levels.

What Dianorm (Gliclazide) Treats: Main Uses and Benefits

Dianorm, which contains the active substance Gliclazide, is a medicine that may be used to help manage the condition of Type 2 diabetes mellitus in adults. This medication is typically considered when modifications to diet and increases in physical activity alone have not resulted in a sufficient level of control over blood sugar.

Gliclazide works to assist the body in regulating blood glucose levels, which is a central component of Type 2 diabetes care. By contributing to an appropriate reduction in HbA1c (a measure of long-term blood glucose control) and fasting blood sugar, the medicine helps support an individual's therapeutic goals.

It is available to help a wide range of adults with Type 2 diabetes who require additional support beyond non-pharmacological interventions. This agent is a widely used option in therapeutic strategies to support optimal management of the condition. For a detailed therapeutic overview of Gliclazide, individuals should consult a healthcare professional or reliable public health resources.

Eligibility and Restrictions for Use

Population Eligibility and Non-Eligibility Status

Dianorm (Gliclazide) is officially documented for use only in adults with Type 2 diabetes mellitus. Its eligibility profile is strictly governed by a regulatory framework that establishes absolute contraindications and conditional restrictions.

Absolute Contraindications

The medicine is formally contraindicated and must not be used in several populations, including patients with Type 1 diabetes mellitus or acute metabolic states such as diabetic keto-acidosis or pre-coma. Use is also prohibited in individuals with known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.

Regulatory documents explicitly forbid use during both pregnancy and lactation/breastfeeding. Furthermore, the combination of Gliclazide with miconazole (systemic or oromucosal gel) is a contra-indicated combination.

Organ Function and Age Restrictions

Patients with severe renal insufficiency or severe hepatic insufficiency are formally ineligible; insulin use is typically recommended in these cases. Conversely, those with mild to moderate renal impairment may use Gliclazide, but regulatory labeling requires careful patient monitoring. Safety and efficacy have not been established in children and adolescents, leading to a formal regulatory non-recommendation for use under 18 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Gliclazide is strictly defined by its potential to cause either an increased or decreased blood glucose-lowering effect when combined with other substances, as documented in official regulatory labels.

Formally Documented Interaction Categories

Category	Interacting Entity (Substance/Condition)	Official Regulatory Status
Contraindicated Combination	Miconazole (systemic route)	Prohibited due to severe potentiation of hypoglycaemic effect.
Potentiation of Effect	Beta-blockers, Fluconazole, ACE Inhibitors, Other Antidiabetic Agents	Increases the risk of hypoglycaemia (low blood sugar).
Reduced Effect	Glucocorticoids (Corticosteroids), Diuretics (Thiazides), Danazol	Risk of hyperglycaemia (high blood sugar) and loss of control.

Specific Substance and Behavioral Constraints

Co-administration with Phenylbutazone (systemic) is not recommended as it increases the hypoglycaemic action, partly by affecting plasma protein binding. The use of Rifampin may increase Gliclazide's metabolism, potentially reducing its therapeutic action over time. Acute intake of alcohol is documented to dangerously potentiate the blood glucose-lowering effect, while chronic consumption may alter Gliclazide metabolism, making avoidance formally advised.

Official prescribing information notes that irregular food intake significantly increases the risk of interaction-related hypoglycaemia, establishing a requirement for a regular eating schedule. Specific caution is noted for interactions with Fluoroquinolones in elderly patients, and interactions may be prolonged in patients with documented hepatic or renal impairment.

Mechanism of Action

How Dianorm (Gliclazide) Works: Mechanism of Action

The mechanism of Gliclazide is centered on stimulating the pancreatic release of insulin, thereby influencing systemic glucose concentration.

Targeted K ATP Channel Inhibition in Pancreatic beta-Cells

Gliclazide's action is initiated by its direct binding to the sulfonylurea receptor 1 ( SUR1) subunit of the ATP-sensitive potassium channel ( K ATP channel) in pancreatic beta-cells. This interaction type is an inhibition that prevents the normal efflux of potassium ions ( K^+) from the cell, which is the immediate biological event that initiates the insulin-releasing cascade.

Ca^2+-Mediated Insulin Secretion Cascade

The closure of the K ATP channel induces membrane depolarization, triggering the opening of voltage-gated calcium channels. The resulting calcium ( Ca^2+) influx is the critical intracellular signal that triggers the fusion of insulin-containing vesicles with the cell membrane, leading to the rapid, glucose-independent secretion of insulin into the circulation.

Modulation of Systemic Glucose Homeostasis

This increased release of insulin acts systemically to enhance glucose uptake by peripheral tissues and suppresses the liver's production of glucose (hepatic glucose output). The resulting physiological change is a decrease in plasma glucose concentration, which is a consequence of enhanced systemic glucose uptake and suppressed hepatic output.

Dosage and Administration Information

The administration of Gliclazide is strictly via the oral route as a long-term treatment for Type 2 diabetes. The medication is available in distinct formulations: Immediate-Release (IR) tablets (40 mg, 80 mg) and Modified-Release (MR) tablets (30 mg, 60 mg, 120 mg), each with specific labeled instructions.

Standard Adult Regimen and Titration

The dosage regimen is determined by the specific formulation. For the Modified-Release tablet, the starting dose is 30 mg taken once daily, with the maximum dose limited to 120 mg per day. The Immediate-Release tablet typically starts at 40 mg to 80 mg daily, with a maximum dose of 320 mg; doses exceeding 160 mg must be administered in two divided doses. Dose adjustments must be incremental, based on metabolic response, and should generally observe an interval of at least one month between changes, though a shorter interval may be considered if initial control is inadequate.

Administration Conditions and Handling

The Modified-Release tablets must be swallowed whole with water at breakfast time to ensure proper intake alignment with regular food consumption. The MR tablet should not be crushed, chewed, or cut, as this would compromise its time-release properties. If a dose is missed, the instruction is to skip the forgotten dose and resume the normal schedule the following day; taking a double dose is explicitly not permitted.

Usage in Specific Populations

For older adults and individuals with mild to moderate renal impairment, the general adult dosing regimen is used, accompanied by careful patient monitoring. Gliclazide is not authorized for use in children and adolescents (lt 18 years), as its safety and efficacy have not been established in this population.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dianorm (Gliclazide)

Core Evidence for Use in Type 2 Diabetes Mellitus

Gliclazide was evaluated in research exploring the control of blood glucose levels in Type 2 diabetes. The research includes numerous short- and intermediate-term Randomized Controlled Trials (RCTs) that research examined outcomes related to changes in blood glucose levels. The most frequently outcomes monitored in these studies included measurements of Glycated Hemoglobin ( HbA1c) level and Fasting Blood Glucose (FBG). Short-term trials consistently monitored measurements of the HbA1c biomarker across various populations, research describing observed shifts. These research efforts contribute to the broader evidence landscape for these specific biomarkers, though the research does not determine whether an individual will respond similarly outside of the study setting.

Research on Long-Term Vascular Outcomes

Beyond short-term blood sugar metrics, large-scale clinical programs studies explored whether the use of Gliclazide in an intensive glucose control setting was associated with long-term vascular outcomes. These complex studies monitored high-level endpoints such as Major Macrovascular and Microvascular Events (e.g., non-fatal heart attack and the progression of kidney issues).

One major long-term trial data show patterns related to a combined primary outcome of vascular events, where the findings described patterns observed in the incidence of new or worsening kidney disease (nephropathy). This specific microvascular outcome was observed in some studies that followed participants for a median of approximately five years. In contrast, findings were mixed regarding the evidence for major macrovascular outcomes, and the overall certainty around the findings remains low when compared to trials using less intensive glucose control strategies.

Evidence in Specific Patient Populations

Gliclazide was evaluated in a broad range of patients, including specific groups research examined within the studies. Studies explored the use of the medicine in older adults (aged 60 and above) and in individuals with co-existing conditions, notably chronic kidney disease (CKD) and those at high cardiovascular risk.

Key Studies & References

Antidiabetic drugs and kidney disease - Swiss Medical Weekly (Review highlighting CKD use of Gliclazide)

Frequently Asked Questions (FAQ)

Common questions about Dianorm (Gliclazide) (FAQ)

Q: Are there any long-term safety concerns associated with taking Dianorm?

Official product information indicates that long-term safety monitoring is required during use. Rare but serious risks involving the blood system, liver function, and severe skin reactions have been formally documented. Furthermore, large-scale studies have been conducted to examine the long-term effects on vascular outcomes.

Q: Is it common to have skin reactions or rash with Gliclazide?

Skin reactions like rash or itching are listed in regulatory documentation, usually classified as uncommon or rare undesirable effects. Severe skin reactions are classified separately as very rare and serious risks.

Q: Does Dianorm (Gliclazide) interact with commonly used over-the-counter pain relievers?

Official safety warnings state that some common non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or aspirin, are documented to strengthen the blood glucose-lowering effect of Gliclazide. This interaction may increase the risk of low blood sugar, or hypoglycemia.

Q: Can Dianorm be taken with blood pressure medication?

Regulatory documents list certain classes of blood pressure medication, such as Beta-blockers and ACE Inhibitors, as agents that may increase the effect of Dianorm. This potentiation may increase the risk of experiencing low blood sugar.

Q: Are there specific foods or supplements that interact with Gliclazide?

The herbal preparation St. John’s Wort is specifically documented in official sources to potentially reduce the intended therapeutic effect of Gliclazide. Furthermore, irregular food intake is noted as a factor that can increase the risk of low blood sugar. This highlights how food consistency relates to the documented risk of low blood sugar.

Q: Is Dianorm (Gliclazide) safe to take for elderly people?

Regulatory documentation confirms that the general adult dosing regimen is used for older adults. However, official warnings indicate that this population may have greater sensitivity to the medicine and could be more susceptible to the risk of low blood sugar (hypoglycemia).

Q: What is the typical time frame to see the expected effects of Dianorm? / Does Dianorm (Gliclazide) work instantly after taking a tablet?

While the physiological effect begins after taking the tablet, official guidelines suggest that consistent metabolic control is achieved over time. Dose adjustments are typically recommended only after at least one month of treatment, indicating that the full therapeutic response requires this assessment period.

Q: Can Dianorm be taken on an empty stomach?

Official instructions specify that the Modified-Release tablets must be taken with breakfast. The risk of experiencing low blood sugar is documented to increase significantly if meals are skipped or if food intake is irregular. Regulatory documents note that irregular food intake increases the documented risk of low blood sugar.

Q: What is the difference between the standard and modified release (MR) versions of Dianorm?

The Modified-Release (MR) and Immediate-Release (IR) forms of Dianorm differ in their strengths and how they are administered. The MR tablet is designed to be swallowed whole and taken once daily for a slow release. The IR tablet may require a divided daily dose, depending on the amount prescribed.

Q: Can Gliclazide affect liver function test results?

Official reports of undesirable effects include instances of raised hepatic enzyme levels. These enzymes are routinely measured as part of liver function tests. Official product information states that treatment may be discontinued if signs of liver disease are observed.

Q: Is Dianorm available as a generic medicine?

Dianorm is a specific trade name used for the active substance Gliclazide. Gliclazide itself is a long-established compound that is widely available as a generic medicine under various brand names globally.

Q: Why is Gliclazide sometimes sold under the name Dianorm?

Dianorm is one of the specific brand names under which the active substance Gliclazide is sold in different regions. This practice of branding an active substance is common in the pharmaceutical industry.

Q: Is Dianorm considered an insulin substitute?

Dianorm (Gliclazide) is officially classified as an insulin secretagogue. Its primary mechanism is to stimulate the pancreas to release more of its own insulin. It is not intended as a substitute for insulin replacement therapy.

Q: How is Dianorm (Gliclazide) different from Metformin? / Is Dianorm the same type of drug as Glipizide?

Dianorm (Gliclazide) and Glipizide both belong to the sulfonylurea pharmacological class of oral antidiabetic agents. Metformin, however, belongs to a different pharmacological class of antidiabetic agents known as biguanides.

Q: Can Dianorm (Gliclazide) cause lightheadedness or dizziness?

Dizziness is listed as one of the possible symptoms that may occur during an episode of low blood sugar (hypoglycaemia), which is the most common side effect associated with Gliclazide.

Q: Is it necessary to adjust my diet while taking Dianorm?

Official prescribing information indicates that Dianorm (Gliclazide) is used in conjunction with both dietary measures and regular exercise. The use of the medicine is not intended to replace the necessity of maintaining standard dietary requirements.

Q: Is there evidence for Gliclazide being used to prevent diabetes?

Gliclazide is officially indicated only for the treatment of Type 2 diabetes mellitus in adults. Regulatory documents do not contain indications for the prevention of diabetes.

Q: What should be done if someone accidentally takes too much Dianorm?

Regulatory guidance indicates that if too much Dianorm is taken, there is a risk of severe low blood sugar (hypoglycemia). Regulatory guidance recommends seeking immediate medical advice from a medical professional or emergency services.

Q: Does using Dianorm require more frequent blood sugar monitoring?

Regulatory documentation states that regular monitoring of blood glucose levels and Glycated Hemoglobin ( HbA1c) is required during the treatment process with Dianorm (Gliclazide).

Q: Is it possible to build a tolerance to Dianorm over time?

Official prescribing information describes a phenomenon known as secondary failure. This is when the blood glucose-lowering efficacy of the medicine may be attenuated, or reduced, over time.

Q: Does Dianorm make people feel more hungry or thirsty?

Increased hunger is a documented symptom that may be associated with low blood sugar (hypoglycemia). Increased thirst, however, is a common symptom of high blood sugar (hyperglycemia), which may indicate the medicine is not working effectively.

Q: Can Dianorm be taken while driving or operating machinery?

Official safety warnings advise that patients should be aware of the risk of low blood sugar and its symptoms. Official safety warnings describe that caution is necessary when driving or operating machinery, especially at the start of treatment, due to the risk of low blood sugar.

Q: Why is it important to take Dianorm at the same time each day?

The requirement for a regular daily dosing schedule is linked to the need for consistent food intake. Irregular mealtimes are documented to significantly increase the risk of experiencing low blood sugar.

Q: What are the signs that Dianorm may not be working effectively?

Signs that the medicine may not be working effectively are generally the documented symptoms of high blood sugar, or hyperglycemia. These include increased thirst, frequent urination, dry mouth, and dry itchy skin.

How should Dianorm (Gliclazide) be stored and disposed of?

How to Store and Dispose of Dianorm (Gliclazide)

Official Storage Requirements

To ensure product stability, Gliclazide tablets must be stored in accordance with official regulatory labeling. This medicinal product requires storage below a maximum temperature, typically 30 C or 25 C, depending on the specific formulation. It is mandatory to store the tablets in the original package to protect from moisture and light.

All Gliclazide tablets must be kept out of the sight and reach of children.

Disposal Instructions

Do not use Gliclazide after the expiry date printed on the packaging. Any unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. The medicine should not be discarded into wastewater or household rubbish, unless specifically instructed otherwise by a local authorized pharmaceutical waste collection program.

Dianorm (Gliclazide)